An observational study in Alzheimer's Disease (AD) and Cognitive Impairment, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Enrolling by invitation at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Observational
The purpose of the BBR is to facilitate scientific research by serving as a local and external resource for the distribution of human blood and CSF biospecimens, together with their corresponding clinical data, to internal and external researchers.
The goals for establishing the BBR are to:
3,771 studies on the registry are indexed under Alzheimer Disease; 886 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 200 across 783 observational studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 330 studies on the registry; 136 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Eligible patients from the Aging Brain and Memory Clinic (ABMC), Cognitive Neurology, or participants who are enrolled in other research projects affiliated with the Cognitive Clinical Research Group or Cognitive Neurology will be invited to participate in the biorepository. This targeted recruitment strategy ensures that participants have relevant clinical profiles, facilitating efficient enrollment and supporting the study's focus on neurodegenerative conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
blood sample will be collected at time of consent
facilitate scientific research
The purpose of the BBR is to advance neurodegenerative disease research by providing high-quality human blood and cerebrospinal fluid (CSF) biospecimens, together with linked clinical, cognitive, imaging, and biomarker data, to internal and external investigators. Successful outcomes will be measured by the utilization of these resources to support biomarker discovery, validation, and implementation studies aimed at improving the diagnosis, prognosis, monitoring, and treatment of neurodegenerative disorders.
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's →